Your browser doesn't support javascript.
loading
Real-World Assessment of Asthma Specialist Visits Among U.S. Patients with Severe Asthma.
Most, Jessica F; Ambrose, Christopher S; Chung, Yen; Kreindler, James L; Near, Aimee; Brunton, Stephen; Cao, Yao; Huang, Huan; Zhao, Xiaohui.
Afiliação
  • Most JF; Jefferson Health/National Jewish Health, Philadelphia, Pa.
  • Ambrose CS; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, Del.
  • Chung Y; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md.
  • Kreindler JL; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md.
  • Near A; Real-World Evidence, IQVIA, Durham, NC.
  • Brunton S; Primary Care Respiratory Group (PCRG), Winnsboro, SC.
  • Cao Y; Real-World Evidence, IQVIA, Durham, NC.
  • Huang H; Real-World Evidence, IQVIA, Durham, NC.
  • Zhao X; Real-World Evidence, IQVIA, Durham, NC. Electronic address: Xiaohui.Zhao2@iqvia.com.
J Allergy Clin Immunol Pract ; 9(10): 3662-3671.e1, 2021 10.
Article em En | MEDLINE | ID: mdl-34148858
ABSTRACT

BACKGROUND:

U.S. guidelines recommend that patients with severe asthma be referred to specialists (allergists/immunologists or pulmonologists) for systematic assessment or comanagement; however, contemporary, real-world data on the frequency and impact of specialist care among U.S. severe asthma patients are lacking.

OBJECTIVES:

To quantify the frequency of asthma specialist visits among U.S. patients with severe asthma, identify patient demographic and clinical characteristics associated with specialist visits and describe health outcomes following specialist care.

METHODS:

Severe asthma patients aged 6 years or older were identified between January 1, 2015, and December 31, 2017, in the IQVIA PharMetrics® Plus database of commercially insured individuals, based on Healthcare Effectiveness Data and Information Set (HEDIS) criteria and Global Initiative for Asthma (GINA) step 4 or 5 treatment regimens. The frequency of asthma specialist (allergist/immunologist or pulmonologist) visits was described over 2 years. Patient characteristics associated with having 1 or more specialist visits were analyzed using multivariate regressions. Asthma exacerbations and health care resource utilization before and after specialist visit were compared.

RESULTS:

Of 54,332 patients identified, 38.2% had 1 or more specialist visits over 2 years. Patient characteristics predictive of specialist visits were asthma exacerbation frequency, younger age, and allergy/respiratory comorbidity burden (all P < .001). Among patients with 1 or more specialist visits, a lower prevalence of asthma exacerbations and rescue inhaler use was observed following the first observed specialist visit.

CONCLUSIONS:

Specialist care was observed in fewer than half of U.S. patients with severe asthma and was least frequent among older adult patients and those with more nonrespiratory comorbidities. Increased specialist involvement in managing severe asthma may help improve care and patient outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Panamá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Panamá